We value innovation, creativity and individual initiative.
Discovering New Approaches to Therapy in the Field of Medicine
We are a publicly traded biotechnology company focused on the development and commercialization of Phorbol 12-myristate 13-acetate (PMA) internal i.d. RP-323, a focused immunotherapy and stem cell activator for treating neurological diseases (CNS).
HypGen Inc is developing a proprietary ‘platform’ technology, a differentiation agent phorbol 12-myristate 13-acetate (PMA) internally called RP-323
A phase I safety study has been completed and the company is now prepared to enter into phase I/II clinical study in Parkinson’s disease in collaboration with a major University Hospital in Atlanta Georgia.